ArticlePharmaceutical research1995
Long-circulating emulsions (oil-in-water) as carriers for lipophilic drugs.
Article in Pharmaceutical research, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 111 citations in OpenAlex.
- Nanoemulsions a Delivery System in the Making for Tumor Targeting Therapeutics: Evaluation and Characterization to Meet Clinical Challenges.Current pharmaceutical biotechnology · 2025Review
- Article
- Article
- A Nano-Emulsion Platform Functionalized with a Fully Human scFv-Fc Antibody for Atheroma Targeting: Towards a Theranostic Approach to Atherosclerosis.International journal of molecular sciences · 2021Article
- Elimination of the biphasic pharmacodynamics of 15d-PGJ2 by controlling its release from a nanoemulsion.International journal of nanomedicine · 2016Article
- The effects of oil-in-water nanoemulsion polyethylene glycol surface density on intracellular stability, pharmacokinetics, and biodistribution in tumor bearing mice.Pharmaceutical research · 2015Article
- Computed tomography-guided screening of surfactant effect on blood circulation time of emulsions: application to the design of an emulsion formulation for paclitaxel.Pharmaceutical research · 2014Article
- Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals.The Journal of nutritional biochemistry · 2014Review
- Tolerance-like innate immunity and spleen injury: a novel discovery via the weekly administrations and consecutive injections of PEGylated emulsions.International journal of nanomedicine · 2014Article
- The shape/morphology balance: a study of stealth liposomes via fractal analysis and drug encapsulation.Pharmaceutical research · 2013Article
- Preparation and characteristics of lipid nanoemulsion formulations loaded with doxorubicin.International journal of nanomedicine · 2013Article
- Encapsulation and release of Amphotericin B from an ABC triblock fluorous copolymer.Pharmaceutical research · 2012Article
- Injectable lipid emulsions-advancements, opportunities and challenges.AAPS PharmSciTech · 2010Review
- A novel camptothecin derivative incorporated in nano-carrier induced distinguished improvement in solubility, stability and anti-tumor activity both in vitro and in vivo.Pharmaceutical research · 2009Article
- Biodistribution characteristics of galactosylated emulsions and incorporated probucol for hepatocyte-selective targeting of lipophilic drugs in mice.Pharmaceutical research · 2004Article
- Reduced phagocytosis of colloidal carriers using soluble CD47.Pharmaceutical research · 2003Article
- Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density.Pharmaceutical research · 2001Article
- Improved DNA/emulsion complex stabilized by poly(ethylene glycol) conjugated phospholipid.Pharmaceutical research · 2001Article
- Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel.Pharmaceutical research · 2000Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRapid clearance of parenterally administered oil-in-water emulsions from blood by the reticuloendothelial system (RES), mainly macrophages of the liver and spleen, has been one of the major obstacles for delivering lipophilic drugs to cells other than those in the RES. The purpose of this study therefore is to overcome this problem and develop emulsions that will have prolonged blood circulation time.
methodsA series of amphipathic polyethylene-glycol (PEG) derivatives have been included as co-emulsifier into emulsions composed of Castor oil and phosphatidylcholine. The effect of amphipathic PEG on reducing the RES uptake and prolonging the blood circulation of the emulsion particles has been tested in vivo using mice as an animal model.
resultsInclusion of PEG derivatives such as Tween-80 or dioleoyl N-(monomethoxy-polyethyleneglycol succinyl)phosphotidylethanolamine (PEG-PE) into emulsions composed of Castor oil and phosphatidylcholine decreases the RES uptake and increases blood residence time of the emulsions. The activity of PEG derivatives in prolonging the circulation time of emulsions depends on the PEG chain length (PEG2000 > PEG5000 > PEG1000, Tween-80) and the PEG density on emulsion surface.
conclusionsInclusion of amphipathic PEG as emulsifier into oil-in-water emulsions is a very effective method to prolong the blood half life of the emulsions. Emulsions with long circulating half life in blood should be very useful as a delivery vehicle for lipophilic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.